News about "Adeno-Associated Virus"

TECPR2 Foundation, Forge Biologics Partner on AAV Gene Therapy

TECPR2 Foundation, Forge Biologics Partner on AAV Gene Therapy

The TECPR2 Research Foundation and Forge Biologics partners to advance development and manufacturing of an investigational AAV gene therapy for TECPR2-related disorder.

Adeno-Associated Virus | 30/09/2026 | By News Bureau

Genprex Selects Andelyn Biosciences for Scale-Up Manufacturing of Diabetes Gene Therapy

Genprex Selects Andelyn Biosciences for Scale-Up Manufacturing of Diabetes Gene Therapy

Genprex’s gene therapy candidate aims to restore insulin-producing function in diabetes by delivering Pdx1 and MafA genes to the pancreas using an AAV vector.

Adeno-Associated Virus | 03/09/2026 | By Akanki

Genprex Partners with US CDMO to Scale Up Diabetes Gene Therapy Manufacturing

Genprex Partners with US CDMO to Scale Up Diabetes Gene Therapy Manufacturing

Genprex has partnered with a US-based CDMO to scale up cGMP manufacturing of its AAV-based diabetes gene therapy candidate, supporting IND-enabling studies and future clinical trials.

Adeno-Associated Virus | 19/08/2026 | By News Bureau |  101

Genethon and Ampersand Biomedicines Partner to Develop Precision Gene Therapy Vectors

Genethon and Ampersand Biomedicines Partner to Develop Precision Gene Therapy Vectors

Genethon and Ampersand Biomedicines join forces to engineer advanced AAV gene therapy vectors designed for greater tissue specificity, potentially enabling safer and more effective treatments for patients with rare genetic disorders.

Adeno-Associated Virus | 25/05/2026 | By News Bureau |  153

NIH-Funded Study Unveils Compact CRISPR System for Targeted In-Body Gene Editing

NIH-Funded Study Unveils Compact CRISPR System for Targeted In-Body Gene Editing

Researchers backed by the National Institutes of Health have developed an enhanced CRISPR enzyme that enables efficient gene editing and fits into viral delivery systems, advancing potential in-body therapies.

Adeno-associated Virus | 15/04/2026 | By News Bureau |  522

FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy

FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy

Affinia Therapeutics receives FDA clearance to begin clinical testing of AFTX-201, a next-generation AAV gene therapy for BAG3-associated dilated cardiomyopathy, with Phase 1/2 UPBEAT trial set to begin in 2026.

Adeno-Associated Virus | 09/02/2026 | By News Bureau |  278


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members